Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2 (2021)

First Author: Pattni K
Attributed to:  Impact of network-structured populations on evolution funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.10.12.21264840

Publication URI: http://dx.doi.org/10.1101/2021.10.12.21264840

Type: Preprint